WO2003008444A3 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells - Google Patents

Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells Download PDF

Info

Publication number
WO2003008444A3
WO2003008444A3 PCT/CA2002/001106 CA0201106W WO03008444A3 WO 2003008444 A3 WO2003008444 A3 WO 2003008444A3 CA 0201106 W CA0201106 W CA 0201106W WO 03008444 A3 WO03008444 A3 WO 03008444A3
Authority
WO
WIPO (PCT)
Prior art keywords
destruction
removal
cells
tumors
conditions requiring
Prior art date
Application number
PCT/CA2002/001106
Other languages
French (fr)
Other versions
WO2003008444A2 (en
Inventor
Paul A Averback
Jack Gemmell
Original Assignee
Nymox Corp
Paul A Averback
Jack Gemmell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2453967A priority Critical patent/CA2453967C/en
Priority to MXPA04000561A priority patent/MXPA04000561A/en
Application filed by Nymox Corp, Paul A Averback, Jack Gemmell filed Critical Nymox Corp
Priority to BRPI0211200A priority patent/BRPI0211200B8/en
Priority to AU2002319050A priority patent/AU2002319050B2/en
Priority to DK02748517T priority patent/DK1417228T3/en
Priority to JP2003514002A priority patent/JP4587667B2/en
Priority to KR1020047000844A priority patent/KR100966232B1/en
Priority to NZ531114A priority patent/NZ531114A/en
Priority to EP02748517A priority patent/EP1417228B1/en
Priority to PL368912A priority patent/PL207588B1/en
Priority to EA200400205A priority patent/EA006603B1/en
Priority to DE60218179T priority patent/DE60218179T2/en
Priority to IL15990302A priority patent/IL159903A0/en
Publication of WO2003008444A2 publication Critical patent/WO2003008444A2/en
Publication of WO2003008444A3 publication Critical patent/WO2003008444A3/en
Priority to IL159903A priority patent/IL159903A/en
Priority to NO20040222A priority patent/NO333999B1/en
Priority to ZA2004/01320A priority patent/ZA200401320B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention relates to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such proteins), the amino acid sequence of which includes at least one amino acid sequence derived from neural thread proteins and other related molecules.
PCT/CA2002/001106 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells WO2003008444A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL15990302A IL159903A0 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
NZ531114A NZ531114A (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
BRPI0211200A BRPI0211200B8 (en) 2001-07-19 2002-07-19 peptides effective in the treatment of tumors and other conditions that require the removal or destruction of cells
AU2002319050A AU2002319050B2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DK02748517T DK1417228T3 (en) 2001-07-19 2002-07-19 Peptides that are effective in treating tumors and other conditions that require the removal or destruction of cells
JP2003514002A JP4587667B2 (en) 2001-07-19 2002-07-19 Peptides effective in treating tumors and other conditions that require removal or destruction of cells
KR1020047000844A KR100966232B1 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2453967A CA2453967C (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP02748517A EP1417228B1 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EA200400205A EA006603B1 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PL368912A PL207588B1 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE60218179T DE60218179T2 (en) 2001-07-19 2002-07-19 PEPTIDES FOR THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS
MXPA04000561A MXPA04000561A (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells.
IL159903A IL159903A (en) 2001-07-19 2004-01-15 Peptides, compositions comprising them and uses thereof for the manufacture of medicaments for the treatment of tumors and other conditions requiring the removal or destruction of cells
NO20040222A NO333999B1 (en) 2001-07-19 2004-01-16 NTP peptides and their use in the preparation of a drug for the treatment of tumors and other conditions requiring cell removal or destruction
ZA2004/01320A ZA200401320B (en) 2001-07-19 2004-02-18 Peptides effective in the treatment for tumors and other conditions requiring the removal ofr destruction of cells

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30616101P 2001-07-19 2001-07-19
US30615001P 2001-07-19 2001-07-19
US60/306,161 2001-07-19
US60/306,150 2001-07-19
US33147701P 2001-11-16 2001-11-16
US60/331,477 2001-11-16

Publications (2)

Publication Number Publication Date
WO2003008444A2 WO2003008444A2 (en) 2003-01-30
WO2003008444A3 true WO2003008444A3 (en) 2003-11-20

Family

ID=27405149

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA2002/001105 WO2003008443A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PCT/CA2002/001106 WO2003008444A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001105 WO2003008443A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Country Status (22)

Country Link
US (2) US7241738B2 (en)
EP (2) EP1417228B1 (en)
JP (4) JP2005507647A (en)
KR (2) KR101005130B1 (en)
CN (1) CN100475843C (en)
AT (1) ATE353914T1 (en)
AU (2) AU2002319049B2 (en)
BR (2) BR0211199A (en)
CA (2) CA2453965C (en)
CY (1) CY1108009T1 (en)
DE (2) DE60218179T2 (en)
DK (1) DK1417228T3 (en)
EA (1) EA006603B1 (en)
ES (2) ES2281529T3 (en)
IL (2) IL159903A0 (en)
MX (1) MXPA04000561A (en)
NO (1) NO333999B1 (en)
NZ (2) NZ531115A (en)
PL (1) PL207588B1 (en)
PT (1) PT1417228E (en)
WO (2) WO2003008443A2 (en)
ZA (1) ZA200401320B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
DE60222745T2 (en) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent USE OF NEUROFILAMENT PROTEINS FOR THE TREATMENT OF TUMORS
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2003008443A2 (en) * 2001-07-19 2003-01-30 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE445714T1 (en) * 2001-12-04 2009-10-15 Millennium Pharm Inc 15603, A MEMBER OF THE HUMAN ION CHANNEL FAMILY
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
BRPI0412664A (en) * 2003-07-15 2006-09-26 Ca Nat Research Council A method for treating a condition characterized by hyperproliferation of skin cells in an at-risk or at-risk individual and using a therapeutically effective amount of a human parathyroid hormone (hpth) cyclic analogue.
EA010687B1 (en) * 2004-02-06 2008-10-30 Нимокс Корпорейшн Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
DK1994152T3 (en) 2006-02-28 2013-03-11 Nymox Corp PEPTIDES EFFECTIVE IN TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING CELL REMOVAL OR DESTRUCTION
CN101400364A (en) * 2006-03-10 2009-04-01 尼莫克斯股份有限公司 Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ES2824683T3 (en) * 2007-10-25 2021-05-13 Toray Industries Inducer of immune response
JP5572938B2 (en) * 2007-10-25 2014-08-20 東レ株式会社 Immune inducer
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
RU2545347C2 (en) * 2008-04-24 2015-03-27 Теримьюнекс Фармасьютикалз, Инк. Peptidyl-diacylglycerides
TWI814373B (en) 2010-09-29 2023-09-01 美商艾澤西公司 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP2016535770A (en) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． Inclusion body for transdermal delivery of therapeutic and cosmetic substances
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948888A (en) * 1988-12-21 1999-09-07 The General Hospital Corporation Neural thread protein gene expression and detection of Alzheimer's disease
WO2002097030A2 (en) * 2001-05-25 2002-12-05 Nymox Corporation Peptides derived from neural thread proteins and their medical use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145285T1 (en) * 1988-12-21 1996-11-15 Gen Hospital Corp EVIDENCE OF A NEUROLOGICAL DISEASE OR A FUNCTIONAL DISORDER
KR20000075748A (en) 1997-02-26 2000-12-26 마빈 씨. 구트리 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
EP1089734A2 (en) * 1998-06-26 2001-04-11 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
WO2000018426A1 (en) * 1998-09-30 2000-04-06 The Institute Of Physical And Chemical Research Apoptosis inducers
WO2000034477A2 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
MXPA01006998A (en) * 1999-01-11 2002-05-06 Leadd Bv Use of apoptosis inducing agents in the treatment of (auto)immune diseases.
EP1161446A1 (en) 1999-03-12 2001-12-12 Human Genome Sciences, Inc. 50 human secreted proteins
CA2365223A1 (en) * 1999-03-19 2000-09-28 Craig A. Rosen 46 human secreted proteins
CA2364209A1 (en) 1999-03-26 2000-10-26 Human Genome Sciences, Inc. 49 human secreted proteins
JP2003535570A (en) * 1999-03-26 2003-12-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 50 human secreted proteins
EP1165827A4 (en) 1999-03-26 2003-05-02 Human Genome Sciences Inc 45 human secreted proteins
CN1300779A (en) 1999-12-22 2001-06-27 上海博德基因开发有限公司 Polypeptide-human neuron linear protein 17 and polynucleotide for coding this polypeptide
CN1300783A (en) 1999-12-23 2001-06-27 上海生元基因开发有限公司 Human neuron linear protein and its coding sequence
US20020127671A1 (en) * 2000-06-26 2002-09-12 Curtis Rory A.J. 52927, a novel human calcium channel and uses thereof
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2003008443A2 (en) * 2001-07-19 2003-01-30 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948888A (en) * 1988-12-21 1999-09-07 The General Hospital Corporation Neural thread protein gene expression and detection of Alzheimer's disease
WO2002097030A2 (en) * 2001-05-25 2002-12-05 Nymox Corporation Peptides derived from neural thread proteins and their medical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FELTKAMP MCW ET AL.: "Efficient MHC Class I-Peptide Is Required But Does Not Ensure MHC Class I-Restricted Immunogenicity", MOLECULAR IMMUNOLOGY, vol. 31, no. 18, December 1994 (1994-12-01), pages 1391 - 1401, XP008018744 *
SIJTS AJAM ET AL.: "Immunodominant Mink Cell Focus-Inducing Murine Leukemia Virus (MuLV)-Encoded CTL Epitope, Identified by its MHC Class I-Binding Motif, Explains MuLV-Type Specificity of MCF-Directed Cytotoxic T Lymphocytes", JOURNAL OF IMMUNOLOGY, vol. 152, 1994, pages 106 - 116, XP002245361 *

Also Published As

Publication number Publication date
ES2281528T3 (en) 2007-10-01
EP1417227B1 (en) 2007-01-10
PL207588B1 (en) 2011-01-31
JP4587667B2 (en) 2010-11-24
US20030109437A1 (en) 2003-06-12
BRPI0211200B8 (en) 2021-07-27
AU2002319049B2 (en) 2007-10-25
PL368912A1 (en) 2005-04-04
DE60217507T2 (en) 2007-11-15
JP5622885B2 (en) 2014-11-12
EP1417228A2 (en) 2004-05-12
KR20040026686A (en) 2004-03-31
CA2453965A1 (en) 2003-01-30
DE60218179T2 (en) 2007-11-22
WO2003008443A3 (en) 2003-11-27
EA200400205A1 (en) 2004-06-24
DK1417228T3 (en) 2007-06-04
DE60217507D1 (en) 2007-02-22
KR100966232B1 (en) 2010-06-25
ES2281529T3 (en) 2007-10-01
US20030096756A1 (en) 2003-05-22
ZA200401320B (en) 2005-01-26
JP2013215191A (en) 2013-10-24
BR0211200A (en) 2004-09-28
EP1417227A2 (en) 2004-05-12
CA2453967A1 (en) 2003-01-30
JP2011152133A (en) 2011-08-11
KR101005130B1 (en) 2011-01-04
CN1649895A (en) 2005-08-03
IL159903A (en) 2010-02-17
MXPA04000561A (en) 2005-02-17
PT1417228E (en) 2007-05-31
BR0211199A (en) 2004-10-26
JP2005506061A (en) 2005-03-03
US7241738B2 (en) 2007-07-10
CN100475843C (en) 2009-04-08
CA2453967C (en) 2014-01-07
IL159903A0 (en) 2004-06-20
NO20040222L (en) 2004-03-19
DE60218179D1 (en) 2007-03-29
JP2005507647A (en) 2005-03-24
WO2003008444A2 (en) 2003-01-30
NO333999B1 (en) 2013-11-11
EP1417228B1 (en) 2007-02-14
EA006603B1 (en) 2006-02-24
NZ531115A (en) 2005-03-24
CY1108009T1 (en) 2013-09-04
BRPI0211200B1 (en) 2020-03-17
CA2453965C (en) 2016-01-19
KR20040018481A (en) 2004-03-03
NZ531114A (en) 2006-12-22
AU2002319050B2 (en) 2008-09-11
ATE353914T1 (en) 2007-03-15
US7192929B2 (en) 2007-03-20
WO2003008443A2 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2003008444A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003044053A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
EP2261247A3 (en) KDR peptides and vaccines comprising the same
EP1857115A3 (en) Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2008014603A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003016342A3 (en) Tumor antigens for prevention and/or treatment of cancer
WO2003008441A3 (en) Moringa seed proteins
WO2003093431A3 (en) Ablated slam-dependent entry
WO2003025014A3 (en) Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
EP1714979A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
NO20040221L (en) Peptides for cell removal or destruction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159903

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000561

Country of ref document: MX

Ref document number: 2453967

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003514002

Country of ref document: JP

Ref document number: 1020047000844

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 177/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002319050

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 531114

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002748517

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200401320

Country of ref document: ZA

Ref document number: 200400205

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20028183320

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002748517

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002748517

Country of ref document: EP